Blogs about HEPH - Stockpickr! Your Source for Stock Ideas

Blogs about HEPH

Blogs	Description	Date Updated
Pre-Market Stock News (MAY 1, 2007)	(AMED) AMEDISYS $0.51 EPS vs $0.50e.(AVP) Avon Products $0.34 EPS vs $0.28e.(BP) BP has new documents that surfaced on corrosion and the company not spending to fix pipelines.(BSX) Boston Scientific names new CFO.(CC) Circuit City lowered guidance and expects a loss; stock down 11%; multiple downgrades.(CE) Celanese $0.91 EPS vs $0.73e.(DCGN) deCODE Genetics announces positive top-line results for Phase I study of DG051 for the prevention of heart attack.(DRV) Debt Resolve to acquire Creditors I...	May 01, 2007
Comfort Zone Investing: Biotech tale - epilogue and lessons learned	Filed under: Comfort Zone InvestingTed Allrich is the founder of The Online Investor and author of the just released book: Comfort Zone Investing: Build Wealth And Sleep Well At Night. In this weekly column, he'll offer advice to investors who are just getting started. The last two columns described my experience with two biotech stocks. One was bad Hollis-Eden Pharmaceuticals (NASDAQ: HEPH). One was good Dendreon Corp. (NASDAQ: DNDN). (Please note that I am not recommending you buy or sell eit...	April 28, 2007
Comfort Zone Investing: Biotech tale - epilogue and lessons learned	Filed under: Comfort Zone InvestingTed Allrich is the founder of The Online Investor and author of the just-released book: Comfort Zone Investing: Build Wealth And Sleep Well At Night. In this weekly column, he'll offer advice to investors who are just getting started. The last two columns described my experience with two biotech stocks. One was bad: Hollis-Eden Pharmaceuticals (NASDAQ: HEPH). One was good: Dendreon Corp. (NASDAQ: DNDN). (Please note that I am not recommending you buy or sell e...	April 28, 2007
Thursday's Top Biotech & Medical Stocks	by H.S. AyoubBioHealth Investor.comBiotechnologyNOVAVAX INC [NVAX] +9.49% REXAHN PHARMACEUTICL [RXHN.OB] +6.67% HESKA CORPORATION [HSKA] +6.57% HOLLIS-EDEN PHARM [HEPH] +6.34% HEMOBIOTECH INC [HMBT.OB] +5.79% Diagnostic Substances MONOGRAM BIOSCIENCES [MGRM] +9.47% SCOLR PHARMA INC [DDD] +6.42% EPICEPT CORPORATION [EPCT] +5.07% AVALON PHARMACEUTIC [AVRX] +3.95% INTERLEUKIN GENETICS [ILI] +3.60% Drug Delivery NSITE VISION INC [ISV] +6.21% COLUMBIA LABS INC [CBRX] +3.45% BIOVAIL CORP [BV...	April 20, 2007
Comfort Zone Investing: A tale of two biotech stocks (part 1)	Filed under: Comfort Zone InvestingTed Allrich is the founder of The Online Investor and author of the just released book: Comfort Zone Investing: Build Wealth And Sleep Well At Night. In this weekly column, he'll offer advice to investors who are just getting started. It was the best of times; it was the worst of times. Too bad that's already been used, because it's the perfect opening for two stocks in the biotech sector. One of them flopped like a boxer hit with a perfect right hook while th...	April 14, 2007
Pre-Market Stock News (MAR 29, 2007)	(ALTR) Altera announced a $0.04 dividend a 50 million share buyback plan.(ALV) Autoliv names new President/CEO.(ANGO) Angiodynamics fell 20% after losing a jury verdict to Diomed.(ATMI) ATMI Inc. lowered guidance.(BA) Boeing gets a 47 plane order for 737 from American Airlines.(BCE) BCE may get a bid of just under $26 Billion from private equity firm KKR.(CAG) ConAgra could be ripe for a break-up to Cramer.(CEO) CNOOC said its annual income rose 22%.(CLAY) Clayton Homes announces that it has agr...	March 29, 2007
StreetInsider.com Unusual 11 Mid-Day Movers 03/16/2007	Bally Total Fitness (NYSE: BFT) 53.5% LOWER; Company engaged Jefferies & Co as financial advisor, sees 'Going Concern', and considers bankruptcy if it's debt isn't restructured. Micromet, Inc. (Nasdaq: MITI) 42% HIGHER; MITI and TRACON Pharmaceuticals announced an agreement granting TRACON exclusive worldwide rights to develop and commercialize Micromet's D93 antibody with a novel mode of action for the treatment of cancer. TRACON Pharmaceuticals was founded in 2005 by Paramount BioSciences, ...	March 16, 2007
Hollis Eden: What Else They Have Under the Hood	Hollis Eden (HEPH), a micro-cap drug development company, is up roughly 7% at $2.68 pre-market after the company announced it was officially shelving its Neumune radiation treatment development because of the government's withdrawal of support. The company's loss of $7.9 million for the quarter equates to a -$0.29 EPS loss after a $200,000 stock option charge. Hollis Eden's CEO discussed with CNBC's Mike Huckman about the drop of the government program on its radiation treatment called ...	March 16, 2007
StreetInsider.com Unusual 11 Mid-Day Movers 03/08/2007	Mamma.com (Nasdaq: MAMA) 34% HIGHER; Reports a Q2 EPS of $0.03, versus the estimate of a $0.08 loss. Revenues were $3.57 million vs. $1.9 million consensus. Hollis-Eden Pharmaceuticals (Nasdaq: HEPH) 32% LOWER; US Dept of HHS didn't approve a contract for the company's radiation treatment. Distributed Energy (Nasdaq: DESC) 25% LOWER; Reports a Q4 adj-loss of $0.19, versus the consensus of a $0.14 loss. Revenues were $13.8 million vs. $15.57 million consensus. Merriman Curhan downgrades th...	March 08, 2007
StreetInsier.com Pre-Open Mover 03/08	StreetInsier.com Pre-Open Mover: Mamma.com (Nasdaq: MAMA) 31% HIGHER; reports a Q2 EPS of $0.03, versus the estimate of a $0.08 loss. Revenues were $3.57 million vs. $1.9 million consensus. Hollis-Eden Pharmaceuticals Inc. (Nasdaq: HEPH) 27% LOWER; US Dept of HHS didn't approve a contract for the company's radiation treatment. Distributed Energy (Nasdaq: DESC) 13% LOWER; reports a Q4 adj-loss of $0.19, versus the consensus of a $0.14 loss. Revenues were $13.8 million vs. $15.57 million ...	March 08, 2007

Enter search text here: